Company profile
Novo Integrated Sciences, Inc.
OTC: NVOS · Healthcare · Medical - Care Facilities
#596 of 1,418 Healthcare companies by revenue50th-percentile growth
EA Score
——FH —DQ 36GM —SS 36
v0.1 · 25/100 weight · pillars only
↑ growth stability, workforce scale · ↓ filing timeliness, market scale
Methodology →Revenue TTM
$13.3M
Rev growth YoY (TTM)
+5.7%
Net income (FY)
-$16.2M
Employees
115
as of 2026-08-28
Market cap
$76.9k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$13.3M$13.3M2024
Net income-$16.2M-$16.2M2024
Operating income-$10.1M-$10.1M2024
Total assets$32.1M$32.1M2024
Liabilities$17.5M$17.5M2024
Equity$14.9M$14.9M2024
Revenue trend
FY2018 – FY2024 · USD
FY18
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2024
By product
Corporate100%
By geography
Not disclosed.
The read
What is Novo Integrated Sciences, Inc.’s revenue?
Novo Integrated Sciences, Inc. booked $13.3M in FY2024 revenue, growing 5.7% year over year — about the middle of the pack among Healthcare companies we track, at a -121.6% net margin.
Peers · Healthcare
Hyperfine, Inc.44DCapsoVision, Inc.37DMicrobix Biosystems Inc.60CMednow Inc.——Tonix Pharmaceuticals Holding Corp.45DRadnostix, Inc.51DNeighbors
King →Key facts
CEORobert Mattacchione
SectorHealthcare
IndustryMedical - Care Facilities
HeadquartersBellevue, WA
ExchangeOTC: NVOS
Employees115
IPO date2021-02-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.